Silence Therapeutics SLN Stock
Silence Therapeutics Price Chart
Silence Therapeutics SLN Financial and Trading Overview
| Silence Therapeutics stock price | 10.68 USD |
| Previous Close | 10.49 USD |
| Open | 10.53 USD |
| Bid | 7.56 USD x 200 |
| Ask | 13.37 USD x 200 |
| Day's Range | 10.32 - 11.25 USD |
| 52 Week Range | 4.19 - 12.19 USD |
| Volume | 89.07K USD |
| Avg. Volume | 426.85K USD |
| Market Cap | 525.49M USD |
| Beta (5Y Monthly) | 1.411 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.62 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.17 USD |
SLN Valuation Measures
| Enterprise Value | 425.54M USD |
| Trailing P/E | N/A |
| Forward P/E | -28.525642 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 626.32306 |
| Price/Book (mrq) | 10.635756 |
| Enterprise Value/Revenue | 507.202 |
| Enterprise Value/EBITDA | -5.987 |
Trading Information
Silence Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.411 |
| 52-Week Change | 76.30% |
| S&P500 52-Week Change | 18.32% |
| 52 Week High | 12.19 USD |
| 52 Week Low | 4.19 USD |
| 50-Day Moving Average | 8.75 USD |
| 200-Day Moving Average | 6.85 USD |
SLN Share Statistics
| Avg. Volume (3 month) | 426.85K USD |
| Avg. Daily Volume (10-Days) | 596.94K USD |
| Shares Outstanding | 47.23M |
| Float | 27.46M |
| Short Ratio | 2.47 |
| % Held by Insiders | 21.76% |
| % Held by Institutions | 44.54% |
| Shares Short | 1.57M |
| Short % of Float | 4.40% |
| Short % of Shares Outstanding | 3.32% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -3565.40% |
| Gross Margin | 79.49% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -29.79% |
| Return on Equity (ttm) | -92.55% |
Income Statement
| Revenue (ttm) | 839K USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | 197.19% |
| Gross Profit (ttm) | 667K USD |
| EBITDA | -71083000 USD |
| Net Income Avi to Common (ttm) | -75039000 USD |
| Diluted EPS (ttm) | -1.62 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 70.08M USD |
| Total Cash Per Share (mrq) | 1.48 USD |
| Total Debt (mrq) | 136K USD |
| Total Debt/Equity (mrq) | 0.28 USD |
| Current Ratio (mrq) | 9.833 |
| Book Value Per Share (mrq) | 1.046 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -65565000 USD |
| Levered Free Cash Flow (ttm) | -45655752 USD |
Profile of Silence Therapeutics
| Country | United States |
| State | N/A |
| City | London |
| Address | 12 Hammersmith Grove |
| ZIP | W6 7AP |
| Phone | 44 20 3457 6900 |
| Website | https://www.silence-therapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 88 |
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Q&A For Silence Therapeutics Stock
What is a current SLN stock price?
Silence Therapeutics SLN stock price today per share is 10.68 USD.
How to purchase Silence Therapeutics stock?
You can buy SLN shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Silence Therapeutics?
The stock symbol or ticker of Silence Therapeutics is SLN.
Which industry does the Silence Therapeutics company belong to?
The Silence Therapeutics industry is Biotechnology.
How many shares does Silence Therapeutics have in circulation?
The max supply of Silence Therapeutics shares is 47.23M.
What is Silence Therapeutics Price to Earnings Ratio (PE Ratio)?
Silence Therapeutics PE Ratio is now.
What was Silence Therapeutics earnings per share over the trailing 12 months (TTM)?
Silence Therapeutics EPS is -1.62 USD over the trailing 12 months.
Which sector does the Silence Therapeutics company belong to?
The Silence Therapeutics sector is Healthcare.
Silence Therapeutics SLN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25913.9 USD — |
+2.13
|
10.13B USD — | 25420.35 USD — | 25967.44 USD — | — - | 10.13B USD — |
|
US Tech Health Care
IXHC
US
|
1241.31 USD — |
+0.58
|
— — | 1233.81 USD — | 1244.91 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2235.3 USD — |
+1.88
|
— — | 2184.88 USD — | 2238.45 USD — | — - | — — |
- {{ link.label }} {{link}}
